Table 2.
Multivariate analysis of risk factors for neutrophil nadir < 500/µL
| OR (95% Ci) | P | Nadir multiplier† | P | |
|---|---|---|---|---|
| Pre-transplant neutrophil level (µL) | ||||
| >2000 | 1.0 | |||
| 500–1999 | 3.55 (2.0–6.2) | <0.0001 | 0.56 (0.42–0.75) | <0.0001 |
| <500 | 5.94 (2.1–17) | 0.0009 | 0.18 (0.12–0.27) | <0.0001 |
| Disease group | ||||
| ALL,AML,MDS,CML | 1.0 | |||
| HL,NHL,CLL | 0.57 (0.3–1.1) | 0.11 | 0.91 (0.66–1.27) | 0.58 |
| MM | 0.24 (0.1–0.6) | 0.002 | 1.54 (0.96–2.47) | 0.08 |
| Donor | ||||
| Related | 1.0 | |||
| Unrelated | 3.62 (1.9–6.8) | <0.0001 | 0.56 (0.39–0.80) | 0.001 |
| Patient age, years | ||||
| <50 | 1.0 | |||
| 50–64 | 1.51 (0.8–2.8) | 0.18 | 0.74 (0.53–1.05) | 0.09 |
| 65+ | 2.40 (0.8–7.2) | 0.12 | 0.72 (0.45–1.16) | 0.18 |
| Donor age, years | ||||
| <50 | 1.0 | |||
| 50+ | 0.87 (0.5–1.7) | 0.68 | 0.87 (0.59–1.27) | 0.47 |
| CD34 cell dose × 106/kg | ||||
| 5.9+ | 1.0 | |||
| <5.9 (lowest quartile) | 1.29 (0.7–2.4) | 0.41 | 0.91 (0.67–1.23) | 0.55 |
| Prior high-intensity transplant | ||||
| No | 1.0 | |||
| Yes* | 0.46 (0.2–0.9) | 0.03 | 1.68 (1.18–2.39) | 0.004 |
| No. of prior chemotherapy regimens | ||||
| 0–3 | 1.0 | |||
| 4+ | 0.95 (0.5–1.7) | 0.87 | 0.92 (0.69–1.23) | 0.59 |
| HCT-CI score | ||||
| 0–2 | 1.0 | |||
| 3+ | 1.12 (0.7–1.9) | 0.66 | 0.89 (0.68–1.15) | 0.37 |
*
Autologous HCT as part of tandem autologous/allogeneic HCT: n=114; failed autologous HCT: n=87; preceding autologous HCT for other disease: n=9; failed allogeneic HCT: n=15.
†
The nadir is a continuous outcome on a log scale – the effects of risk factors are expressed as multipliers. For example, a pre-transplant count <500 reduces the nadir by 82%; a diagnosis of MM increases the nadir by 54%.